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Abstract
Levetiracetam is a widely used, effective and usually well-tolerated anti-epileptic medicine. It
is mostly excreted by kidneys and requires dose adjustment according to the glomerular
filtration rate. Very few case reports have been published in the literature about levetiracetam
causing acute kidney injury (AKI). We present a case of a 26-year-old male with a seizure
disorder on levetiracetam, presented with status epilepticus requiring intubation for airway
protection. He received 4 g of intravenous levetiracetam as a loading dose and continued with a
maintenance dose of 750 mg intravenous every 12 hours. He had signs of AKI on day two and
creatinine eventually reached a maximum level of 12.2 mg/dL. His kidney function improved to
his new baseline in a period of 30 days without requiring renal replacement therapy. He did not
have significant rhabdomyolysis and his kidney function started improving right after his anti-
epileptic therapy was switched to valproic acid pointing towards levetiracetam as the primary
cause of kidney injury. Clinicians should be aware that levetiracetam can cause AKI on patients
with a seizure disorder, especially when administered in high doses. Kidney function should be
monitored closely and patients should be treated aggressively with intravenous fluids when
they have any signs of rhabdomyolysis to prevent further kidney damage.
Categories: Internal Medicine, Neurology, Nephrology
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Introduction
Levetiracetam is currently one of the most commonly used anti-epileptic drugs (AEDs). Due to
its mechanism of action not binding it to plasma proteins and not being dependent on the
cytochrome p450 system, its pharmacokinetic interactions are minimal. Primary elimination of
levetiracetam occurs through renal excretion and dose adjustments are necessary for patients
with moderate to severe kidney impairment [1-3]⁠. The most commonly reported side effects of
levetiracetam are somnolence, asthenia, dizziness, headache, and rarely behavioral adverse
effects [4] ⁠. Despite its mechanism of action and renal excretion, there has been scant literature
of acute kidney injury (AKI) secondary to levetiracetam use [5-8]⁠. On the other hand, a
retrospective population-based cohort study involving 3,980 patients on levetiracetam
treatment reported no significant risk of developing AKI within 180 days [9] ⁠. Herein we report a
case of AKI caused by levetiracetam, which was administered with a high loading dose in a
critical unit setting.
Case Presentation
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A 26-year-old Hispanic male with a past medical history only significant for epilepsy was
witnessed by family members to have five episodes of tonic-clonic seizures without regaining
consciousness between seizure episodes. As per emergency medical services (EMS) reported,
the patient was found lying on the floor with fecal and urinary incontinence. Initial vital signs
by EMS showed a blood pressure (BP) of 183/108 mmHg, heart rate (HR) of 103 beats per minute
(bpm), and blood glucose of 302 mg/dL. He was able to mumble some answer verbally but
remained disoriented. As the patient was being transferred to the ambulance, he became
aggressive and combative. He was administered 10 mg midazolam intramuscularly and brought
in the ED at Brookdale University Hospital Medicine Center. Prior to the presentation, home
medications included levetiracetam 750 mg tablets twice daily with which he was not fully
compliant as per his family. Chart review revealed multiple ED visits for seizures due to non-
compliance with the medication. In the ED, he received another dose of midazolam, 4 mg to
terminate the residual seizure activity and also received haloperidol and ketamine due to
agitation with combativeness after his initial seizure episode. Vital signs in the ED were within
normal limits except a HR of 142 bpm. Electrocardiogram showed sinus tachycardia. The
patient remained afebrile, but it was noted that his BP began to rise and was recorded at
133/109 mmHg. Soon thereafter, the patient was noticed to be in a phase of status epilepticus
and eventually was intubated for airway protection.
Physical examination revealed the patient to be intubated and sedated, equal-sized pupils
reactive to light, intact brainstem reflexes, no signs of major trauma on his body. He received 4
g of intravenous levetiracetam as a loading dose and was continued with 1000 mg of
levetiracetam intravenously every 12 hours thereafter. Initial laboratory investigations revealed
an elevated lactic acid level of >12 mmol/L, creatinine level of 0.9 mg/dL and creatinine kinase
level of 1004 U/L. Clinical laboratory data has been shown in Table 1. His baseline creatinine
level was within normal limits at 0.9 mg/dL about four years ago and he did not have any
previous history of kidney disease. Venous blood gas showed a pH of 7.07 and bicarbonate level
of 14.4 mmol/L indicating metabolic acidosis most likely due to prolonged seizure activity.
Urine toxicology was positive for cannabinoids. CT imaging of the head was negative for acute
pathology.
Test Reference Range Result
White Blood Cell Count 4.10 - 10.10 10x3/uL 25.90 (H)
Hemoglobin 12.9 - 16.7 g/dL 14.8
Platelets 153 - 328 10x3/uL 416 (H)
Neutrophils, Absolute 1.40 - 6.80 10x3/uL 22.50 (H)
Lymphocytes, Absolute 1.10 - 2.90 10x3/uL 2.6
Monocytes, Absolute 0.20 - 1.00 10x3/uL 0.7
Eosinophils, Absolute 0.00 - 0.40 10x3/uL 0.1
Basophils, Absolute 0.00 - 0.10 10x3/uL 0.1
Glucose 74 - 106 mg/dL 145 (H)
Blood Urea Nitrogen 9.0 - 20.0 mg/dL 16
Creatinine 0.66 - 1.25 mg/dL 1.22
Sodium 133 - 145 mEq/L 137
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Potassium 3.5 - 5.1 mEq/L 4.5
Chloride 98 - 107 mEq/L 109 (H)
Bicarbonate 22 - 30 mEq/L 19 (L)
Calcium 8.4 - 10.2 mg/dL 10.8 (H)
Anion Gap 8-12 mEq/L 9
Protein, Total 6.3 - 8.2 g/dL 9.5 (H)
Albumin 3.5 - 5.0 g/dL 5.3 (H)
Bilirubin, Total 0.2 - 1.3 mg/dL 1
Alanine transaminase (ALT) 21 - 72 U/L 72
Aspartate transaminase (AST) 17 - 59 U/L 43
Lactate 0.70 - 2.10 mmol/L >12 (H)
Creatinine Kinase (CPK) 55 - 170 U/L 1004 (H)
Urine sodium 30.0 - 90.0 mEq/L 96.0 (H)
Urine potassium mEq/L 22.2
Urine protein 5.0 - 11.0 mg/dL 95.0 (H)
Urine creatinine mg/dL 127.2
Urine urea nitrogen mg/dL 87
TABLE 1: Initial laboratory investigations
The patient was transferred to the intensive care unit and repeat laboratory testing the next day
showed blood urea nitrogen of 17 mg/dL and significant elevation in creatinine level to 3.27
mg/dL without a significant increase in creatinine kinase 1377 U/L (reference value: 55-170
U/L). Urine electrolytes were obtained to investigate the acute rise in creatinine (Table 1) and
FeNa (fraction excretion of sodium) was calculated at 8%. Initial urinalysis showed large blood
but only 0-3 red blood cells on high power field microscopy, The patient also had iso-osmotic
urine with a specific gravity of 1.010 and high urine sodium (96 mEq/L). He did not receive any
intravenous contrast, had any other medications with known nephrotoxicity or had any
episodes of hypotension, which might compromise kidney perfusion and cause AKI. 
The patient was assessed by a neurologist and valproic acid 500 mg twice daily was added to the
anti-epileptic regimen to control seizures and levetiracetam was stopped since it was thought
to be the culprit for AKI. Urine output was noted to decrease to 60 cc per hour and then the
patient entered an oliguric phase. The patient received intravenous furosemide to keep him in
non-oliguric and also received half normal saline interchangeably with 5% dextrose in water for
volume expansion. The patient soon began to undergo brisk diuresis (up to 4L of urine per day)
in the recovery phase of acute tubular necrosis (ATN). Creatinine levels continued trending
down. Ultrasound of the retro-peritoneal organs showed normal kidneys without any signs of
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hydronephrosis. The patient’s urine output was monitored closely and he received large
amounts of intravenous fluids in the recovery phase. His creatinine level came back to its new
baseline level of 1.36 mg/dL after 20 days without requiring renal replacement therapy. Blood
urea nitrogen, creatinine, and CPK trends have been shown in Figures 1-3, respectively. The
patient was extubated successfully after 12 days, remained seizure-free and discharged home
with outpatient follow-up. The patient has remained seizure-free and renal function has
remained stable 30 days after discharge.
FIGURE 1: Blood urea nitrogen trend
FIGURE 2: Creatinine trend
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FIGURE 3: Creatinine kinase trend
Discussion
Due to its favorable safety profile, levetiracetam is a widely used and well-tolerated medication
for different types of seizure disorders with minimal side effects. However, due to its renal
excretion, there is a possibility of renal side effects and there remains a paucity in the literature
about levetiracetam causing AKI. Our case demonstrates that levetiracetam may cause AKI,
especially when it is administered with high loading doses.
Levetiracetam is a highly effective anti-epileptic medication with a high therapeutic index and
good bioavailability. It minimally binds to proteins in the blood and reaches steady-state
concentrations rapidly. Its interaction with liver-metabolized medications is limited since it is
not dependent on the cytochrome p450 enzyme system. Levetiracetam is mostly (60%) excreted
in the urine with no modifications and a fraction (24%) of it gets inactivated in the circulatory
system before being excreted in the urine. Due to primarily being excreted in the urine, its dose
should be adjusted according to creatinine clearance [1] ⁠.
The most common adverse reactions secondary to levetiracetam use are fatigue, dizziness,
headache and somnolence [4,10,11]⁠. In a large, open-label, community study on safety and
efficacy of levetiracetam, 1,030 patients being treated for partial-onset seizures showed no
evidence of kidney injury [4] ⁠. In another open label, multi-center, single-arm study on 99
patients who were treated with 1000-3000 mg/day levetiracetam for refractory partial-onset
seizures, patients' blood chemistry was followed up while on therapy. They reported no
significant changes in patient’s blood urea nitrogen and creatinine levels, except they found
blood in the urine of 10 patients, of whom nine were women who were perimenstrual [11].
Moreover, levetiracetam induced kidney injury has been reported in very few cases. In a case of
a previously healthy 23-year-old woman who presented with new-onset seizures and was
started levetiracetam 500 mg twice daily, on day two of therapy she had a rise in her blood urea
nitrogen (20 mg/dL) and creatinine (2.48 mg/dL) levels from a normal baseline. Levetiracetam
therapy was stopped and she started taking phenytoin for seizure prevention. Her kidney
function improved to her baseline on follow-up physical examination two months after
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discharge [5] ⁠. Another case of a 17-year-old female who was started on levetiracetam (250 mg
twice daily) for new-onset partial complex seizures, presented to a local ED 10 days later with
gastrointestinal side effects. She was found to have elevated creatinine of 3.3 mg/dL from a
normal baseline and also had +3 blood and +3 protein in her dipstick urine test. Subsequent
kidney biopsy confirmed the diagnosis of interstitial nephritis. Her kidney function recovered
completely after 10 days of initiating oral prednisone treatment and switching levetiracetam to
oxcarbazepine for seizure prevention [7] ⁠. A third case of a 16-year-old, previously healthy male,
who presented with generalized tonic-clonic seizures and was started levetiracetam therapy
(750 mg twice daily) had a rise in his creatinine level (2.2 mg/dL) on day two from a normal
baseline. The patient also complained of muscle pain and labs were significant for
rhabdomyolysis with peak creatinine kinase level of 15,111 U/l, primarily contributing to AKI.
Levetiracetam therapy was stopped on day five of his treatment and the patient was switched
to divalproex sodium therapy for seizure prevention and received intravenous fluid
resuscitation. His creatinine level normalized on day seven and the patient was safely
discharged home [8]. A fourth case of a previously healthy 45-year-old male who started taking
levetiracetam (starting dose was 500 mg twice daily which later gradually increased to 3000
mg/day) for seizure prevention due to newly discovered astrocytoma. He experienced
progressively worsening gastrointestinal symptoms (mainly intractable nausea) and had an
increased serum creatinine to 3.59 mg/dL from a normal baseline. Levetiracetam was the only
medication he received during over the two month period and his fractional excretion of
sodium (FeNa) was calculated more than 1%, indicating intrinsic causes of kidney injury rather
than pre-renal AKI from dehydration. Levetiracetam was tapered off and he started taking
lacosamide for seizure prevention. His creatinine level normalized to 1.34 mg/dL over one
month [6].
Conclusions
To summarize, levetiracetam can cause AKI on patients with a seizure disorder, more
commonly when used in high doses as was seen in our case. In addition, rhabdomyolysis might
contribute to kidney injury in patients with prolonged seizure activity. In these circumstances,
levetiracetam therapy should be stopped immediately and patients should continue their
treatment with an alternative anti-epileptic medication for seizure prevention, along with
intravenous fluid resuscitation and motorization of kidney function. Kidney function usually
recovers in a period of seven days to 30 days with appropriate therapy and follow-up according
to previously reported case reports.
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